Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lamifiban.

M Dooley1, K L Goa

  • 1Adis International Limited, Auckland, Mairangi Bay, New Zealand. demail@adis.co.nz

Drugs
|April 3, 1999
PubMed
Summary
This summary is machine-generated.

Lamifiban, a glycoprotein IIb/IIIa antagonist, did not significantly reduce short-term clinical events in non-ST elevation myocardial infarction patients. However, longer-term data showed a significant benefit when combined with aspirin and heparin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation.

Transplantation proceedings·2017
Same author

Morphological appearance of uterine cavity on ultrasound prior to development of intrauterine adhesions.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2017
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice.

Internal medicine journal·2016
Same author

The impact of the introduction of an acute sedation practice guideline.

Acta neuropsychiatrica·2016
Same author

Sport, exercise and the menstrual cycle: where is the research?

British journal of sports medicine·2016
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Platelet aggregation is crucial in thrombotic events like myocardial infarction.
  • Glycoprotein IIb/IIIa receptor antagonists offer a targeted approach to inhibit platelet activation.
  • Lamifiban is a selective, reversible, nonpeptide antagonist targeting the glycoprotein IIb/IIIa receptor.

Purpose of the Study:

  • To evaluate the efficacy and safety of lamifiban in patients with non-ST elevation myocardial infarction or unstable angina.
  • To compare lamifiban's effectiveness against standard antiplatelet and anticoagulant therapies.

Main Methods:

  • Intravenous administration of lamifiban at varying doses.
  • Clinical trials (PARAGON A, Canadian Lamifiban Study) involving patients with non-ST elevation myocardial infarction or unstable angina.

Related Experiment Videos

  • Comparison of lamifiban with aspirin, heparin, or both.

    • Main Results:

    • No significant difference in 30-day clinical events between lamifiban and standard therapy (aspirin +/- heparin).
    • PARAGON A showed significantly lower 6-month clinical events with lamifiban (plus aspirin +/- heparin) versus standard heparin and aspirin.
    • Increased bleeding complications were observed with lamifiban, particularly when co-administered with heparin.

    Conclusions:

    • Lamifiban demonstrated a potential for improved long-term outcomes in non-ST elevation myocardial infarction when used with aspirin and heparin.
    • The short-term efficacy was not superior to standard care, and bleeding risk requires careful management.
    • Ongoing trials like PARAGON B are crucial for definitive assessment of lamifiban's role in acute coronary syndromes.